In a new job - April 29, 2019
Fredrik Haavind is new Head of Legal & Compliance at Nordic Nanovector
Haavind has 16 years of broad legal and compliance experience in Norwegian and International businesses, including international contracts law, governance and compliance, M&A, corporate and securities laws and regulations, with experience from in-house legal departments, law firms and the courts. Haavibd joins Nordic Nanovector from Fugro N.V., a global provider of geo-intelligence listed on Euronext, […]
Clinical Trials - May 30, 2018
Nordic Nanovector’s Paradigme trial approved to start
The Phase 2b trial with Betalutin (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics (REK) in Norway. Nordic Nanovector has now received all necessary approvals to begin PARADIGME in Norway and will commence start-up activities with the selected clinical sites immediately with […]
In a new job - February 1, 2018
New appointment for Nordic Nanovector
Nordic Nanovector announces that Malene Brondberg has been appointed as Vice President, Investor Relations and Corporate Communications. She will lead the engagement and communication with the investment community, media and analysts. 20 year’s experience Malene brings over 20 years’ experience, including her roles as a sell-side healthcare analyst and as Global Head of Research and […]
Clinical Trials - December 11, 2017
Updated results from Nordic Nanovector’s LYMRIT trial
Nordic Nanovector has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory (R/R) indolent NHL (iNHL) at the 59th Annual ASH meeting (9-12 December 2017 in Atlanta, GA, USA). The updated data continue to highlight Betalutin’s clinical profile as a single agent for treatment of R/R iNHL, and […]
In a new job - August 3, 2017
New Head of Medical Affairs at Nordic Nanovector
Nordic Nanovector has appointed Dr. Reza Safaei, MD as Head of Medical Affairs. Dr. Safaei will lead the development and execution of Nordic Nanovector’s medical affairs strategy for Betalutin. He will be responsible for building a team of field-based Medical Science Liaisons (MSL) with initial focus on the US, developing strong relationships with global experts […]
Clinical Trials - March 17, 2017
First patient dosed in Nordic Nanovector study
Nordic Nanovector announces that the first patient has been dosed in its Phase 1 study evaluating Betalutin (177Lu-satetraxetan-lilotomab), a novel CD37 targeting antibody-radionuclide conjugate, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) – the “LYMRIT 37-05” trial. “We are excited to begin this study to evaluate Betalutin in patients with relapsed DLBCL who are […]
